Mutant proteinase-inhibitors and uses thereof

Details Mutant proteinase-inhibitors and uses thereof Mutant proteinase-inhibitors and uses thereof

2007-09-04

2007-09-04

Campell, Bruce R. (Department: 1654)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Enzyme inactivation by chemical treatment

Reexamination Certificate

active

10197258

ABSTRACT:
A library of mutants of metastable proteins, such as proteinase inhibitors, can be screened for the specific loss of a wild-type capability to bind an antibody, yielding valuable drug-design information which otherwise is unavailable. By this approach, for example, a mutant proteinase inhibitor can be obtained that has the amino acid sequence of a wild-type protein, or an active fragment thereof, save for the presence of one or more mutations in at least one epitope, thereby altering interaction of the mutant with an anti-proteinase inhibitor antibody.

REFERENCES:
patent: 6103498 (2000-08-01), Lawrence et al.
patent: 6489143 (2002-12-01), Lawrence et al.
International Search Report of PCT/US02/22822.
Lawrence et al., “Serpin Reactive Center Loop Mobility is Required for Inhibitor Function but Not for Enzyme Recognition,”The Journal of Biological Chemistry(Nov. 4, 1994), vol. 269, No. 44. pp. 27657-27662.
Berkenpas et al., “Molecular evolution of plasminogen activator inhibitor-1 functional stability,”The EMBO Journal(1995), vol. 14, No. 13, pp. 2969-2977.
Debrock et al., “Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms,”Biochimica et Biophysica Acta(1997), vol. 1337, pp. 257-266.
Debrock et al., “Cloning of a singing-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate,”Gene(1997), vol. 189, pp. 83-88.
Doolittle, “Angiotensinogen Is Related to the Antitrypsin-Antithrombin-Ovalbumin Family,”Science(Oct. 28, 1983), vol. 222, pp. 417-419.
Eitzman et al., “Peptide-Mediated Inactivation of Recombinant and Platelet Plasminogen Activator Inhibitor-1 In Vitro,”J. Clin. Invest.(May 1995), vol. 95, pp. 2416-2420.
Fay et al., “Platelets Inhibit Febrinolysis In Vitro by Both Plasminogen Activator Inhibitor-1 Dependent and -Independent Mechanisms,”Blood(Jan. 15, 1994), vol. 83, 351-356.
Ginsburg et al., “cDNA Cloning of Human Plasminogen Activator-Inhibitor from Endothelial Cells,”J. Clin. Invest.(Dec. 1986), vol. 78, pp. 1673-1680.
Huber et al., “Implications of the Three-Dimensional Structure of α1-Aantitrypsin for Structure and Function of Serpins,”Biochemistry(Nov. 14, 1989), vol. 28, No. 23, pp. 8951-8966.
Kvassman et al., “The Acid Stabilization of Plasminogen Activator Inhibitor-1 Depends on Protonation of a Single Group That Affects Loop Insertion into β-Sheet A,”The Journal of Biological Chemistry(Nov. 17, 1995), vol. 270, No. 46, pp. 27942-27947.
Lawrence et al., “Purification of active human plasminogen activator inhibitor 1 fromEscherichia coli,” Eur. J. Biochem.(1989), vol. 186, pp. 523-533.
Lawrence et al., “Structure-Function Studies of the SERPIN Plasminogen Activator Inhibitor Type 1,”The Journal of Biological Chemistry(Nov. 25, 1990), vol. 265, No. 33, pp. 20293-20301.
Lawrence et al., “Serpin-Protease Complexes Are Trapped as Stable Acyl-Enzyme Intermediates,”The Journal of Biological Chemistry(Oct. 27, 1995), vol. 270, No. 43, pp. 25309-25312.
Lawrence et al., “Localization of Vitronection Binding Domain in Plasminogen Activator Inhibitor 1,”The Journal of Biological Chemistry(May 27, 1994), vol. 269, No. 21, pp. 15223-15228.
Levi et al., “Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Pormotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis,”Circulation(Jan. 1992), vol. 85, No. 1, pp. 305-312.
Lobermann et al., “Human α1-Proteianse Inhibitor,”J. Mol. Biol.(1984), vol. 177, pp. 531-556.
Loskutoff et al., “Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells,”Proc. Natl. Acad. Sci.(May 1983), vol. 80, pp. 2956-2960.
Ny et al., “Cloning and Sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor,”Proc. Natl. Acad. Sci.(Sep. 1986), vol. 83, pp. 6776-6780.
Olson et al., “Role of the Catalytic Serine in the Interactions of Serine Proteinases with Protein Inhibitors of the Serpin Family,”The Journal of Biological Chemistry(Dec. 15, 1995), vol. 270, No. 50, pp. 30007-30017.
Sherman et al., “Saturation Mutagenesis of the Plasminogen Activator Inhibitor-1 Reactive Center,”The Journal of Biological Chemistry(Apr. 15, 1992), vol. 267, No. 11, pp. 7588-7595.
Sherman et al., “Identification of Tissue-type Plasminogen Activator-specific Plasminogen Activator Inhibitor-1 Mutants,”The Journal of Biological Chemistry(Apr. 21, 1995), vol. 270, No. 16, pp. 9301-9306.
Shubeita et al., “Mutational and Immunochemical Analysis of Plasminogen Activator Inhibitor 1,”,The Journal of Biological Chemistry(Oct. 25, 1990), vol. 265, No. 30, pp. 18379-18385.
Van Mourik et al., “Purification of an Inhibitor of Plasminogen Activator (Antiactivator) Synthesized by Endothelial Cells,”The Journal of Biological Chemistry(Dec. 10, 1984), vol. 259, No. 23, pp. 14914-14921.

Affiliated with

Also associated with

Rating

Mutant proteinase-inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutant proteinase-inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant proteinase-inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3798854